Mutations near amino end of alpha1(I) collagen cause combined osteogenesis imperfecta/Ehlers-Danlos syndrome by interference with N-propeptide processing
- PMID: 15728585
- DOI: 10.1074/jbc.M414698200
Mutations near amino end of alpha1(I) collagen cause combined osteogenesis imperfecta/Ehlers-Danlos syndrome by interference with N-propeptide processing
Abstract
Patients with OI/EDS form a distinct subset of osteogenesis imperfecta (OI) patients. In addition to skeletal fragility, they have characteristics of Ehlers-Danlos syndrome (EDS). We identified 7 children with types III or IV OI, plus severe large and small joint laxity and early progressive scoliosis. In each child with OI/EDS, we identified a mutation in the first 90 residues of the helical region of alpha1(I) collagen. These mutations prevent or delay removal of the procollagen N-propeptide by purified N-proteinase (ADAMTS-2) in vitro and in pericellular assays. The mutant pN-collagen which results is efficiently incorporated into matrix by cultured fibroblasts and osteoblasts and is prominently present in newly incorporated and immaturely cross-linked collagen. Dermal collagen fibrils have significantly reduced cross-sectional diameters, corroborating incorporation of pN-collagen into fibrils in vivo. Differential scanning calorimetry revealed that these mutant collagens are less stable than the corresponding procollagens, which is not seen with other type I collagen helical mutations. These mutations disrupt a distinct folding region of high thermal stability in the first 90 residues at the amino end of type I collagen and alter the secondary structure of the adjacent N-proteinase cleavage site. Thus, these OI/EDS collagen mutations are directly responsible for the bone fragility of OI and indirectly responsible for EDS symptoms, by interference with N-propeptide removal.
Similar articles
-
Y-position cysteine substitution in type I collagen (alpha1(I) R888C/p.R1066C) is associated with osteogenesis imperfecta/Ehlers-Danlos syndrome phenotype.Hum Mutat. 2007 Apr;28(4):396-405. doi: 10.1002/humu.20456. Hum Mutat. 2007. PMID: 17206620
-
Molecular mechanism of alpha 1(I)-osteogenesis imperfecta/Ehlers-Danlos syndrome: unfolding of an N-anchor domain at the N-terminal end of the type I collagen triple helix.J Biol Chem. 2006 Mar 10;281(10):6463-70. doi: 10.1074/jbc.M511830200. Epub 2006 Jan 5. J Biol Chem. 2006. PMID: 16407265
-
Helical mutations in type I collagen that affect the processing of the amino-propeptide result in an Osteogenesis Imperfecta/Ehlers-Danlos Syndrome overlap syndrome.Orphanet J Rare Dis. 2013 May 21;8:78. doi: 10.1186/1750-1172-8-78. Orphanet J Rare Dis. 2013. PMID: 23692737 Free PMC article.
-
Consortium for osteogenesis imperfecta mutations in the helical domain of type I collagen: regions rich in lethal mutations align with collagen binding sites for integrins and proteoglycans.Hum Mutat. 2007 Mar;28(3):209-21. doi: 10.1002/humu.20429. Hum Mutat. 2007. PMID: 17078022 Free PMC article. Review.
-
Inherited disorders of collagen gene structure and expression.Am J Med Genet. 1989 Sep;34(1):72-80. doi: 10.1002/ajmg.1320340114. Am J Med Genet. 1989. PMID: 2683783 Review.
Cited by
-
Multiple dermatofibromas in a patient with Ehlers-Danlos syndrome: a case report.J Med Case Rep. 2024 Aug 31;18(1):417. doi: 10.1186/s13256-024-04628-7. J Med Case Rep. 2024. PMID: 39215353 Free PMC article.
-
Update on the Genetics of Osteogenesis Imperfecta.Calcif Tissue Int. 2024 Aug 11. doi: 10.1007/s00223-024-01266-5. Online ahead of print. Calcif Tissue Int. 2024. PMID: 39127989 Review.
-
Echocardiographic abnormalities and joint hypermobility in Chinese patients with Osteogenesis imperfecta.Orphanet J Rare Dis. 2024 Mar 12;19(1):116. doi: 10.1186/s13023-024-03089-x. Orphanet J Rare Dis. 2024. PMID: 38475860 Free PMC article.
-
Exposure to SARS-CoV-2 and Infantile Diseases.Glob Med Genet. 2023 May 2;10(2):72-78. doi: 10.1055/s-0043-1768699. eCollection 2023 Jun. Glob Med Genet. 2023. PMID: 37144240 Free PMC article.
-
Extracellular matrix in skin diseases: The road to new therapies.J Adv Res. 2023 Sep;51:149-160. doi: 10.1016/j.jare.2022.11.008. Epub 2022 Dec 5. J Adv Res. 2023. PMID: 36481476 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases
Miscellaneous
